{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T12:31:43Z","timestamp":1777984303726,"version":"3.51.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:00:00Z","timestamp":1776902400000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Guangxi University of Chinese Medicine Joint Fund Project","award":["2024LZ006"],"award-info":[{"award-number":["2024LZ006"]}]},{"name":"the Self-funded Research Project of the Guangxi Autonomous Region Administration of Traditional Chinese Medicine","award":["GXZYB20220409"],"award-info":[{"award-number":["GXZYB20220409"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Primary membranous nephropathy (PMN) is a leading cause of nephrotic syndrome in adults. In some patients, PMN can be severe or continue to worsen even after 6 months of supportive treatment. Rituximab and cyclophosphamide with steroids are used to treat moderate-risk or high-risk PMN patients, but the comparative efficacy and safety of rituximab and cyclophosphamide with steroids in patients with PMN remains debated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched PubMed, Embase and the Cochrane Library for the time period through November 2025 to identify randomized controlled trials and cohort studies that evaluated rituximab compared with cyclophosphamide for the treatment of PMN. The primary outcomes were complete remission (CR), partial remission (PR), and total remission (TR\u2009=\u2009PR+CR). The secondary outcomes included the relapse rate, adverse events (AEs), and serious adverse events (SAEs). The random effects model (DerSimonian\u2013Laird method) was used to estimate relative risks (RRs) with 95% confidence intervals (CIs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Eleven studies (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u20091068) were eligible for final inclusion. Rituximab showed similar efficacy to cyclophosphamide with steroids in inducing complete or partial remission at 6 months (RR, 0.82; 95% CI, 0.60\u20131.10;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.19;\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u20090%) and 12 months (RR, 0.85; 95% CI, 0.66\u20131.10;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.21;\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u20090%). Similarly, rates of CR were comparable between the two treatment groups at 6 months (RR, 0.97; 95% CI, 0.33\u20132.89;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.95;\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u20090%) and 12 months (RR, 0.54; 95% CI, 0.26\u20131.12;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.10;\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u20090%). There were no significant differences in the incidence of AEs or SAEs between RTX and cyclophosphamide with steroids. The RRs were 0.76 (95% CI, 0.46\u20131.28;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.30;\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u200951%) and 1.00 (95% CI, 0.50\u20132.00;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20091.00;\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u20090%), respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The current limited evidence suggests that RTX treatment has comparable efficacy and safety to cyclophosphamide with steroids in PMN patients at moderate risk or high risk. Further large-scale, longer follow-up, well-designed RCTs on head-to-head comparisons of the safety and efficacy of rituximab versus cyclophosphamide with steroids are urgently needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12882-026-04895-0","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T19:34:09Z","timestamp":1773689649000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative efficacy and safety of rituximab versus cyclophosphamide with steroids in primary membranous nephropathy: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"27","author":[{"given":"Fangjiao","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenxin","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maorong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peiyu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanfang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuguang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanlei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yifeng","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,16]]},"reference":[{"issue":"9","key":"4895_CR1","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nrneph.2017.92","volume":"13","author":"P Ruggenenti","year":"2017","unstructured":"Ruggenenti P, Fervenza FC, Remuzzi G. Treatment of membranous nephropathy: time for a paradigm shift. Nat Rev Nephrol. 2017;13(9):563\u201379.","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"4895_CR2","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41572-021-00303-z","volume":"7","author":"P Ronco","year":"2021","unstructured":"Ronco P, Beck L, Debiec H, et al. Membranous nephropathy. Nature reviews. Disease primers. 2021;7(1):69.","journal-title":"Disease primers"},{"issue":"2","key":"4895_CR3","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1093\/ndt\/gfq665","volume":"26","author":"A McGrogan","year":"2011","unstructured":"McGrogan A, Franssen CF, de Vries CS. The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. Nephrol Dial Transpl. 2011;26(2):414\u201330.","journal-title":"Nephrol Dial Transpl"},{"issue":"4","key":"4895_CR4","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s00281-014-0423-y","volume":"36","author":"H Debiec","year":"2014","unstructured":"Debiec H, Ronco P. Immunopathogenesis of membranous nephropathy: an update. Semin Immunopathol. 2014;36(4):381\u201397.","journal-title":"Semin Immunopathol"},{"issue":"8","key":"4895_CR5","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1111\/nep.12478","volume":"20","author":"V Kumar","year":"2015","unstructured":"Kumar V, Ramachandran R, Kumar A, et al. Antibodies to m-type phospholipase A2 receptor in children with idiopathic membranous nephropathy. Nephrol (Carlton). 2015;20(8):572\u20135.","journal-title":"Nephrol (Carlton)"},{"issue":"2","key":"4895_CR6","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1681\/ASN.2016070776","volume":"28","author":"AS De Vriese","year":"2017","unstructured":"De Vriese AS, Glassock RJ, Nath KA, Sethi S, Fervenza FC. A Proposal for a Serology-Based Approach to Membranous Nephropathy. J Am Soc Nephrol. 2017;28(2):421\u201330.","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"4895_CR7","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.kint.2016.09.048","volume":"91","author":"DC Cattran","year":"2017","unstructured":"Cattran DC, Brenchley PE. Membranous nephropathy: integrating basic science into improved clinical management. Kidney Int. 2017;91(3):566\u201374.","journal-title":"Kidney Int"},{"issue":"3","key":"4895_CR8","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1111\/j.1523-1755.2004.00873.x","volume":"66","author":"S Troyanov","year":"2004","unstructured":"Troyanov S, Wall CA, Miller JA, Scholey JW, Cattran DC. Idiopathic membranous nephropathy: definition and relevance of a partial remission. Kidney Int. 2004;66(3):1199\u2013205.","journal-title":"Kidney Int"},{"issue":"2","key":"4895_CR9","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1056\/NEJM199307083290203","volume":"329","author":"A Schieppati","year":"1993","unstructured":"Schieppati A, Mosconi L, Perna A, et al. Prognosis of untreated patients with idiopathic membranous nephropathy. N Engl J Med. 1993;329(2):85\u20139.","journal-title":"N Engl J Med"},{"issue":"5","key":"4895_CR10","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1038\/ki.1995.453","volume":"48","author":"C Ponticelli","year":"1995","unstructured":"Ponticelli C, Zucchelli P, Passerini P, et al. A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int. 1995;48(5):1600\u20134.","journal-title":"Kidney Int"},{"issue":"6","key":"4895_CR11","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1681\/ASN.2007020166","volume":"18","author":"V Jha","year":"2007","unstructured":"Jha V, Ganguli A, Saha TK, et al. A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. J Am Soc Nephrol. 2007;18(6):1899\u2013904.","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"4895_CR12","first-page":"Cd004293","volume":"2014","author":"Y Chen","year":"2014","unstructured":"Chen Y, Schieppati A, Chen X, et al. Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome. Cochrane Database Syst Rev. 2014;2014(10):Cd004293.","journal-title":"Cochrane Database Syst Rev"},{"issue":"4s","key":"4895_CR13","first-page":"S1","volume":"100","author":"KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases","year":"2021","unstructured":"KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4s):S1\u2013276.","journal-title":"Kidney Int"},{"issue":"5","key":"4895_CR14","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","volume":"8","author":"D Moher","year":"2010","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg (London England). 2010;8(5):336\u201341.","journal-title":"Int J Surg (London England)"},{"issue":"1","key":"4895_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1\u201312.","journal-title":"Control Clin Trials"},{"key":"4895_CR16","unstructured":"Wells GA, S B, O\u2019Connel D, Peterson J, Welch V, Losos M. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2012. http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp."},{"issue":"11","key":"4895_CR17","doi-asserted-by":"publisher","first-page":"982","DOI":"10.7326\/0003-4819-135-11-200112040-00010","volume":"135","author":"LL Kjaergard","year":"2001","unstructured":"Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med. 2001;135(11):982\u20139.","journal-title":"Ann Intern Med"},{"issue":"11","key":"4895_CR18","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539\u201358.","journal-title":"Stat Med"},{"key":"4895_CR19","doi-asserted-by":"crossref","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360.","DOI":"10.1136\/bmj.327.7414.557"},{"issue":"3","key":"4895_CR20","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177\u201388.","journal-title":"Control Clin Trials"},{"issue":"4","key":"4895_CR21","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.kint.2020.10.014","volume":"99","author":"G Fern\u00e1ndez-Ju\u00e1rez","year":"2021","unstructured":"Fern\u00e1ndez-Ju\u00e1rez G, Rojas-Rivera J, Logt AV, et al. The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy. Kidney Int. 2021;99(4):986\u201398.","journal-title":"Kidney Int"},{"issue":"1","key":"4895_CR22","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3109\/1354750X.2014.993708","volume":"20","author":"AS Medrano","year":"2015","unstructured":"Medrano AS, Escalante EJ, C\u00e1ceres CC, et al. Prognostic value of the dynamics of M-type phospholipase A2 receptor antibody titers in patients with idiopathic membranous nephropathy treated with two different immunosuppression regimens. Biomarkers. 2015;20(1):77\u201383.","journal-title":"Biomarkers"},{"issue":"4","key":"4895_CR23","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1681\/ASN.2020071091","volume":"32","author":"F Scolari","year":"2021","unstructured":"Scolari F, Delbarba E, Santoro D, et al. Rituximab or Cyclophosphamide in the Treatment of Membranous Nephropathy: The RI-CYCLO Randomized Trial. J Am Soc Nephrol. 2021;32(4):972\u201382.","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"4895_CR24","first-page":"545","volume":"35","author":"S Suresh","year":"2025","unstructured":"Suresh S, Konnur A, Rajapurkar MM, Gang S, Hegde UN, Patel H. Low-Dose Rituximab vs. Modified Ponticelli Regimen in the Treatment of Primary Membranous Nephropathy \u2013 A Randomized Controlled Trial. Indian J Nephrol. 2025;35(5):545\u201352.","journal-title":"Indian J Nephrol"},{"issue":"6","key":"4895_CR25","first-page":"1307","volume":"46","author":"YX Nie Limin","year":"2023","unstructured":"Nie Limin YX, Rong Xue Z, Shanshan Z, Bing, et al. Effecy of rituximab combined with cyclophosphamide in treatment of idiopathic membranous nephropathy effect and on immune function of patients. Drug Evaluation Res. 2023;46(6):1307\u201312.","journal-title":"Drug Evaluation Res"},{"issue":"2","key":"4895_CR26","doi-asserted-by":"publisher","first-page":"2409353","DOI":"10.1080\/0886022X.2024.2409353","volume":"46","author":"Y Wang","year":"2024","unstructured":"Wang Y, Ma X, Yang X, et al. A multicenter retrospective study on comparing the efficacy and safety of the therapy of intermittent cyclophosphamide and corticosteroids versus rituximab for primary membranous nephropathy. Ren Fail. 2024;46(2):2409353.","journal-title":"Ren Fail"},{"issue":"1","key":"4895_CR27","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1186\/s12882-024-03912-4","volume":"25","author":"L Lu","year":"2024","unstructured":"Lu L, Cai S, Zhu H, et al. Comparations of efficacy and safety of rituximab, calcineurin inhibitors and cyclophosphamide in primary membranous nephropathy: a single-center retrospective analysis. BMC Nephrol. 2024;25(1):473.","journal-title":"BMC Nephrol"},{"issue":"5","key":"4895_CR28","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1159\/000540548","volume":"10","author":"X Hu","year":"2024","unstructured":"Hu X, Ren H, Xu J, et al. Treatment of Membranous Nephropathy in Chinese Patients: Comparison of Rituximab and Intravenous Cyclophosphamide with Steroids. Kidney Dis (Basel). 2024;10(5):359\u201368.","journal-title":"Kidney Dis (Basel)"},{"issue":"2","key":"4895_CR29","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1159\/000518609","volume":"146","author":"R Ramachandran","year":"2022","unstructured":"Ramachandran R, Prabakaran R, Priya G, et al. Immunosuppressive Therapy in Primary Membranous Nephropathy with Compromised Renal Function. Nephron. 2022;146(2):138\u201345.","journal-title":"Nephron"},{"issue":"2","key":"4895_CR30","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s40620-020-00781-6","volume":"34","author":"R Fenoglio","year":"2021","unstructured":"Fenoglio R, Baldovino S, Sciascia S, et al. Efficacy of low or standard rituximab-based protocols and comparison to Ponticelli\u2019s regimen in membranous nephropathy. J Nephrol. 2021;34(2):565\u201371.","journal-title":"J Nephrol"},{"issue":"9","key":"4895_CR31","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1681\/ASN.2016091022","volume":"28","author":"J van den Brand","year":"2017","unstructured":"van den Brand J, Ruggenenti P, Chianca A, et al. Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy. J Am Soc Nephrol. 2017;28(9):2729\u201337.","journal-title":"J Am Soc Nephrol"},{"key":"4895_CR32","doi-asserted-by":"publisher","first-page":"515","DOI":"10.2147\/ITT.S512451","volume":"14","author":"Z Zhou","year":"2025","unstructured":"Zhou Z, Zou Y, Ke B, Shen W. How to Choose Treatment Regimens for Idiopathic Membranous Nephropathy Patients with PLA2R-Negative: A Single-Center Retrospective Cohort Study. ImmunoTargets therapy. 2025;14:515\u201322.","journal-title":"ImmunoTargets therapy"},{"issue":"5","key":"4895_CR33","first-page":"657","volume":"30","author":"S Wu","year":"2025","unstructured":"Wu S, Yu Q, Yang Q, et al. Comparing the efficacy and safety of cyclophosphamide and rituximab in idiopathic membranous nephropathy. Chin J Clin Pharmacol Ther. 2025;30(5):657\u201364.","journal-title":"Chin J Clin Pharmacol Ther"},{"key":"4895_CR34","doi-asserted-by":"publisher","first-page":"1548679","DOI":"10.3389\/fneph.2025.1548679","volume":"5","author":"B Mao","year":"2025","unstructured":"Mao B, Han J, Wang J, Ye K. Efficacy and safety of rituximab for membranous nephropathy in adults: a meta-analysis of RCT. Front Nephrol. 2025;5:1548679.","journal-title":"Front Nephrol"},{"key":"4895_CR35","unstructured":"Mathew GG, Sundaramurthy S, Muthuperumal P, Jayaprakash V. Low-dose rituximab in the treatment of primary membranous nephropathy: a systematic review and meta-analysis. G Ital Nefrol. 2024;41(5)."},{"issue":"1","key":"4895_CR36","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s12882-023-03307-x","volume":"24","author":"C Xue","year":"2023","unstructured":"Xue C, Wang J, Pan J, et al. Cyclophosphamide induced early remission and was superior to rituximab in idiopathic membranous nephropathy patients with high anti-PLA2R antibody levels. BMC Nephrol. 2023;24(1):280.","journal-title":"BMC Nephrol"},{"issue":"2","key":"4895_CR37","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.nephro.2021.10.002","volume":"18","author":"JY Ou","year":"2022","unstructured":"Ou JY, Chen YW, Li TL, et al. Evaluation of efficacy of rituximab for membranous nephropathy: A systematic review and meta-analysis of 11 studies. Nephrol Ther. 2022;18(2):104\u201312.","journal-title":"Nephrol Ther"},{"key":"4895_CR38","doi-asserted-by":"publisher","first-page":"107376","DOI":"10.1016\/j.intimp.2021.107376","volume":"94","author":"P Dai","year":"2021","unstructured":"Dai P, Xie W, Yu X, Sun J, Wang S, Kawuki J. Efficacy and cost of different treatment in patients with idiopathic membranous nephropathy: A network meta-analysis and cost-effectiveness analysis. Int Immunopharmacol. 2021;94:107376.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"4895_CR39","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1186\/s40001-025-03597-x","volume":"30","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Chen H, Zhang H, Huang Y. Evaluating rituximab against cyclophosphamide or cyclosporine in idiopathic membranous nephropathy: a meta-analysis. Eur J Med Res. 2025;30(1):1228.","journal-title":"Eur J Med Res"},{"key":"4895_CR40","doi-asserted-by":"crossref","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629\u201334.","DOI":"10.1136\/bmj.315.7109.629"},{"issue":"4","key":"4895_CR41","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.2307\/2533446","volume":"50","author":"CB Begg","year":"1994","unstructured":"Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088\u2013101.","journal-title":"Biometrics"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-026-04895-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-04895-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-04895-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T05:53:28Z","timestamp":1776923608000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12882-026-04895-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,16]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4895"],"URL":"https:\/\/doi.org\/10.1186\/s12882-026-04895-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8173549\/v1","asserted-by":"object"}]},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,16]]},"assertion":[{"value":"21 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"256"}}